BSE Live
Sep 25, 16:01Prev. Close
1076.25
Open Price
1075.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Sep 25, 15:49Prev. Close
1080.30
Open Price
1066.10
Bid Price (Qty.)
1071.40 (4)
Offer Price (Qty.)
0.00 (0)
Cash Flow of Jubilant Pharmova (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
Net Profit/Loss Before Extraordinary Items And Tax | 37.60 | 41.70 | 79.34 | 82.25 | 273.17 | |
Net CashFlow From Operating Activities | 135.60 | 143.20 | -65.12 | -3.55 | 608.38 | |
Net Cash Used In Investing Activities | -2.30 | -40.30 | 31.07 | 93.10 | 177.96 | |
Net Cash Used From Financing Activities | -156.80 | -77.80 | 22.51 | -107.37 | -781.65 | |
Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | -61.06 | |
Net Inc/Dec In Cash And Cash Equivalents | -23.50 | 25.10 | -11.53 | -17.82 | -56.38 | |
Cash And Cash Equivalents Begin of Year | 36.10 | 11.00 | 22.53 | 40.33 | 96.70 | |
Cash And Cash Equivalents End Of Year | 12.60 | 36.10 | 10.99 | 22.51 | 40.33 |
30.07.2025
Jubilant Pharmo Consolidated June 2025 Net Sales at Rs 1,900.70 crore, up 9.76% Y-o-Y
30.07.2025
Jubilant Pharmo Standalone June 2025 Net Sales at Rs 59.50 crore, down 64.31% Y-o-Y
20.07.2025
16.06.2025
30.07.2025
Jubilant Pharmo Consolidated June 2025 Net Sales at Rs 1,900.70 crore, up 9.76% Y-o-Y
30.07.2025
Jubilant Pharmo Standalone June 2025 Net Sales at Rs 59.50 crore, down 64.31% Y-o-Y
16.05.2025
Jubilant Pharmo Consolidated March 2025 Net Sales at Rs 1,928.80 crore, up 9.68% Y-o-Y
16.05.2025
Jubilant Pharmo Standalone March 2025 Net Sales at Rs 217.30 crore, up 5.59% Y-o-Y
18.01.2021
Jubilant Life Sciences Q3 PAT seen up 14.9% YoY to Rs. 238 cr: Prabhudas Lilladher
12.07.2019
Jubilant Life Sciences Q1 PAT may dip 10.4% YoY to Rs. 181.4 cr: Prabhudas Lilladher
12.04.2019
Jubilant Life Sciences Q4 PAT seen up 36.3% YoY to Rs. 211.2 cr: Prabhudas Lilladher
11.01.2019
Jubilant Life Science Q3 PAT seen up 13.8% YoY to Rs. 241.8 cr: ICICI Direct